2.97
2.97 (0%)
As of Feb 14, 2025
Vistagen Therapeutics, Inc. [VTGN]
Source:
Company Overview
Vistagen Therapeutics, Inc. is a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on our deep understanding of nose-to-brain neurocircuitry.
| Country | United States |
| Headquarters | san francisco, california |
| Phone Number | (650) 577-3600 |
| Industry | manufacturing |
| CEO | Shawn K. Singh |
| Website | www.vistagen.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.2 |
| Operating Profit | $-15.1 |
| Net Income | $-14.1 |
| Net Cash | $-44.5 |
Profit Ratios
| Gross Margin | $0.2 |
| Operating Margin | -6,461.5 |
| Profit as % of Revenues | -1.7% |
| Profit as % of Assets | -13.1% |
| Profit as % of Stockholder Equity | -17.4% |
Management Effectiveness
| Return on Equity | -17.4% |
| Return on Assets | -15.3% |
| Turnover Ratio | 0.2% |
| EBITA | $-15.1 |
Balance Sheet and Cash Flow Measures
| Total Assets | $92.3 |
| Total Liabilities | $11.2 |
| Operating Cash Flow | $-32 |
| Investing Cash Flow | $-13.7 |
| Financing Cash Flow | $1.3 |
